U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H20N2O2.ClH
Molecular Weight 296.7929
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FENSPIRIDE HYDROCHLORIDE

SMILES

c1ccc(cc1)CCN2CCC3(CC2)CN=C(O)O3.Cl

InChI

InChIKey=FIKFLLIUPUVONI-UHFFFAOYSA-N
InChI=1S/C15H20N2O2.ClH/c18-14-16-12-15(19-14)7-10-17(11-8-15)9-6-13-4-2-1-3-5-13;/h1-5H,6-12H2,(H,16,18);1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.4609
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C15H20N2O2
Molecular Weight 260.3321
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Fenspiride is an oxazolidinone spiro compound used as a drug in the treatment of certain respiratory diseases. It is approved for use in Russia for the treatment of acute and chronic inflammatory diseases of ENT organs and the respiratory tract (like rhinopharyngitis, laryngitis, tracheobronchitis, otitis and sinusitis), as well as for maintenance treatment of asthma. Fenspiride is marketed under the brand names Eurespal, Pneumorel, SYRESP, Oxofen and others. Erespal (fenspiride) is a drug with a bronchodilator and spasmolytic effect, which is often used in the complex therapy of bronchial asthma. Fenspiride has a clinically proven ability to increase the activity of the cilia of the bronchial ciliated epithelium, normalize the secretion of the bronchi and reduce its viscosity. Effectively removes bronchial obstruction, restores pulmonary gas exchange. Inhibits the metabolism of arachidonic acid, in parallel blocking histamine H1-receptors, since it is histamine that stimulates the chemical reactions of the transformation of arachidonic acid into the final metabolites-factors of inflammation. Reduces the production of other mediators of inflammation - serotonin and bradykinin. It blocks α-adrenergic receptors, the activation of which increases the secretion of bronchial glands. The complex effect of fenspiride reduces the pathological effect of a number of factors that promote hypersecretion of anti-inflammatory substances and cause obstruction of the bronchial tree. Has a pronounced antispasmodic and myotropic effect.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P16599
Gene ID: 103694380|||24835
Gene Symbol: Tnf
Target Organism: Rattus norvegicus (Rat)
4.16 null [pIC50]
3.44 null [pIC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Erespal

Approved Use

The drug is indicated in the complex therapy of respiratory diseases (upper and lower divisions): pharyngitis; Rhinopharyngitis; laryngitis; tracheitis; Tracheobronchitis; Bronchitis (with or without chronic respiratory failure); bronchial asthma; Respiratory symptoms with influenza, measles and whooping cough; sinusitis; otitis; Infection of the respiratory system, in the symptomatic complex of which there is a cough.
Primary
Erespal

Approved Use

The drug is indicated in the complex therapy of respiratory diseases (upper and lower divisions): pharyngitis; Rhinopharyngitis; laryngitis; tracheitis; Tracheobronchitis; Bronchitis (with or without chronic respiratory failure); bronchial asthma; Respiratory symptoms with influenza, measles and whooping cough; sinusitis; otitis; Infection of the respiratory system, in the symptomatic complex of which there is a cough.
Primary
Erespal

Approved Use

The drug is indicated in the complex therapy of respiratory diseases (upper and lower divisions): pharyngitis; Rhinopharyngitis; laryngitis; tracheitis; Tracheobronchitis; Bronchitis (with or without chronic respiratory failure); bronchial asthma; Respiratory symptoms with influenza, measles and whooping cough; sinusitis; otitis; Infection of the respiratory system, in the symptomatic complex of which there is a cough.
Primary
Erespal

Approved Use

The drug is indicated in the complex therapy of respiratory diseases (upper and lower divisions): pharyngitis; Rhinopharyngitis; laryngitis; tracheitis; Tracheobronchitis; Bronchitis (with or without chronic respiratory failure); bronchial asthma; Respiratory symptoms with influenza, measles and whooping cough; sinusitis; otitis; Infection of the respiratory system, in the symptomatic complex of which there is a cough.
Primary
Eurespal

Approved Use

Indications: Rinofaringitis, laryngitis — otitis, sinusitis — rinotraheobronhit — bronchitis — bronchial asthma (maintenance therapy) respiratory effects in measles, pertussis and influenza (syrup).
Primary
Eurespal

Approved Use

Indications: Rinofaringitis, laryngitis — otitis, sinusitis — rinotraheobronhit — bronchitis — bronchial asthma (maintenance therapy) respiratory effects in measles, pertussis and influenza (syrup).
PubMed

PubMed

TitleDatePubMed
[Effectiveness of fenspiride in patients with chronic obstructive bronchitis].
2001
[Experience in treating patients with chronic obstructive bronchitis with fenspirid].
2002
Detection of fenspiride and identification of in vivo metabolites in horse body fluids by capillary gas chromatography-mass spectrometry: administration, biotransformation and urinary excretion after a single oral dose.
2002 Feb 5
[ENT inflammation and importance of fenspiride].
2002 Sep
[Bronchial inflammation during chronic bronchitis, importance of fenspiride].
2002 Sep
[Erespal effectiveness in exudative otitis media].
2003
[Fenspiride-a new alternative on the therapy of obstructive lung disease].
2003 Apr-Jun
[Acute intoxication with fenspiride].
2004
Efficacy of supplemental anti-inflammatory therapy with fenspiride in chronic obstructive and nonobstructive bronchitis.
2005
[Potential of antiinflammatory therapy in patients with chronic obstructive lung disease].
2005
[Effectiveness and tolerance of fenspiride treatment in chronic sinusitis. Results of the Polish multicenter study].
2005
[The effect of fenspiride on the number of exacerbations and the time of first exacerbation in patients with chronic bronchitis].
2005 Aug
[Fenspiride in patients with acute bronchitis].
2005 Jul
[Usefulness of fenspiride in the treatment of acute otitis media in children].
2005 Jun
[Anti-inflammatory therapy of paranasal sinuses diseases].
2006
Comparison of fenspiride with beclomethasone as adjunctive anti-inflammatory treatment in patients with chronic obstructive pulmonary disease.
2006
[Erespal in combined therapy of acute rhinosinusitis].
2006
[New pharmaceuticals in treatment of chronic dust bronchitis].
2007
[The effectiveness of fenspiride in the treatment of patients with chronic obstructive pulmonary disease].
2007
[Hearing rehabilitation in patients with acute otitis media treated with fenspiride].
2008
[Clinicofunctional condition and quality of life in patients with chronic obstructive pulmonary disease before and after outpatient treatment with fenspiride].
2008
[The role of expired air moisture condensate in assessment of pulmonary inflammation in patients with chronic obstructive pulmonary disease].
2008
[Pathogenetic therapy for inflammatory diseases of the middle ear].
2009
[Experience with fenspiride in a rhinosurgeon's practice].
2009
[Efficiency of combination therapy for acute otitis media].
2010
[Pathogenetic correction of postoperative inflammation in modern rhinosurgery].
2010
[Experience in using erespal in the treatment of acute respiratory diseases in children in outpatient practice].
2010
Patents

Sample Use Guides

Tablets: One tablet (80 mg) twice-thrice a day. The maximum dose for a daily intake is 240 mg (3 tablets). Syrup: For 45-90 milliliters (3-6 tablespoons, respectively) per day.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment:: Fenspiride (10(-7)-10(-5) M) inhibited the histamine H1 receptor-induced Ca2+ increase in a lung epithelial cell line. Fenspiride (10(-5) M) abolished both phases of histamine-induced arachidonic acid release. https://www.ncbi.nlm.nih.gov/pubmed/9652346
Fenspiride (10(-6) to 10(-4) M) inhibited the nonadrenergic, noncholinergic (NANC) component of the contraction of the guinea-pig isolated main bronchus induced by EFS. Fenspiride significantly affected contractions induced by exogenously added substance P or [Nle10]-NKA(4-10) only at concentrations higher than 10(-3) M. In the guinea-pig perfused lung, fenspiride inhibited low pH- but not capsaicin-evoked release of CGRP. At higher concentrations (10(-4) M to 3x10(-4) M) fenspiride exhibited a significant inhibitory effect both on the cholinergic component of contractile response induced by EFS in the guinea-pig isolated main bronchus and on exogenously added acetylcholine.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:50:45 UTC 2021
Edited
by admin
on Fri Jun 25 21:50:45 UTC 2021
Record UNII
832NBX878V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FENSPIRIDE HYDROCHLORIDE
MART.   MI   USAN   WHO-DD  
USAN  
Official Name English
NSC-757825
Code English
FENSPIRIDE HYDROCHLORIDE [MART.]
Common Name English
NAT-333
Code English
FENSPIRIDE HYDROCHLORIDE [MI]
Common Name English
FENSPIRIDE HCL
Common Name English
FENSPIRIDE HYDROCHLORIDE [USAN]
Common Name English
NDR-5998A
Code English
FENSPIRIDE HYDROCHLORIDE [WHO-DD]
Common Name English
8-PHENETHYL-1-OXA-3,8-DIAZASPIRO(4.5)DECAN-2-ONE MONOHYDROCHLORIDE
Systematic Name English
1-OXA-3,8-DIAZASPIRO(4,5)DECAN-2-ONE, 8-(2-PHENYLETHYL)-, MONOHYDROCHLORIDE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C257
Created by admin on Fri Jun 25 21:50:45 UTC 2021 , Edited by admin on Fri Jun 25 21:50:45 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL576127
Created by admin on Fri Jun 25 21:50:45 UTC 2021 , Edited by admin on Fri Jun 25 21:50:45 UTC 2021
PRIMARY
FDA UNII
832NBX878V
Created by admin on Fri Jun 25 21:50:45 UTC 2021 , Edited by admin on Fri Jun 25 21:50:45 UTC 2021
PRIMARY
PUBCHEM
68626
Created by admin on Fri Jun 25 21:50:45 UTC 2021 , Edited by admin on Fri Jun 25 21:50:45 UTC 2021
PRIMARY
DRUG BANK
DBSALT002867
Created by admin on Fri Jun 25 21:50:45 UTC 2021 , Edited by admin on Fri Jun 25 21:50:45 UTC 2021
PRIMARY
RXCUI
236281
Created by admin on Fri Jun 25 21:50:45 UTC 2021 , Edited by admin on Fri Jun 25 21:50:45 UTC 2021
PRIMARY RxNorm
CAS
5053-08-7
Created by admin on Fri Jun 25 21:50:45 UTC 2021 , Edited by admin on Fri Jun 25 21:50:45 UTC 2021
PRIMARY
MERCK INDEX
M5296
Created by admin on Fri Jun 25 21:50:45 UTC 2021 , Edited by admin on Fri Jun 25 21:50:45 UTC 2021
PRIMARY Merck Index
ECHA (EC/EINECS)
225-752-9
Created by admin on Fri Jun 25 21:50:45 UTC 2021 , Edited by admin on Fri Jun 25 21:50:45 UTC 2021
PRIMARY
EPA CompTox
5053-08-7
Created by admin on Fri Jun 25 21:50:45 UTC 2021 , Edited by admin on Fri Jun 25 21:50:45 UTC 2021
PRIMARY
MESH
C084775
Created by admin on Fri Jun 25 21:50:45 UTC 2021 , Edited by admin on Fri Jun 25 21:50:45 UTC 2021
PRIMARY
NCI_THESAURUS
C80551
Created by admin on Fri Jun 25 21:50:45 UTC 2021 , Edited by admin on Fri Jun 25 21:50:45 UTC 2021
PRIMARY
EVMPD
SUB02128MIG
Created by admin on Fri Jun 25 21:50:45 UTC 2021 , Edited by admin on Fri Jun 25 21:50:45 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY